Providence Swedish Cancer Institute Research
@ProvSwedCancRes
Followers
97
Following
24
Media
10
Statuses
275
Sharing #Cancer #Research news updates from Providence Swedish Cancer Institute. Tweets do not constitute medical advice
Seattle, WA, USA
Joined December 2021
Tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage #SCLC (DeLLphi-303): a multicentre, phase 1b study Presented today @IASLC #WCLC2025, 5 pm CEST https://t.co/pGzVM7xha3
@ProvSwedCancRes
1
4
12
Dr. Swathi Namburi @ProvSwedCancRes coauthors a clinical trial in @JCO_ASCO of new #bispecific antibody for #myeloma #immunotherapy
ascopubs.org
PURPOSEWe present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in relapsed/...
0
0
1
Dr. Dubard-Gault cancer geneticist and preventionist @ProvSwedCancRes @ProvSwedish presents a rare cancer syndrome due to a newly described variant in JCO Precision Oncology:
ascopubs.org
0
0
0
Dr. Aliea Herbert studies #cancerrehab in improving #survivorship after #HSCT with colleagues @EmoryUniversity @MayoClinic @MDAndersonNews
pubmed.ncbi.nlm.nih.gov
Rehabilitation practices during HSCT varied among the largest volume cancer centers in the United States, but most centers provided skilled therapy, utilized objective, clinician and patient reported...
0
0
0
Dr. Krish Patel @KrishPatelMD works with docs @WUSTLmed and @OHSUKnight to make #carT therapy for #lymphoma more patient friendly and cost-effective through #outpatient delivery
link.springer.com
Advances in Therapy - Chimeric antigen receptor T-cell (CAR T) therapies have transformed diffuse large B-cell lymphoma (DLBCL) treatment. It is important to better understand their use in Medicare...
0
0
0
Dr. Devarakonda @ProvSwedCancRes participates in a study of new #targetedtherapy for #lungcancer #nsclc
https://t.co/9wPb5kVMUO 🫁
jtd.amegroups.org
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer
0
0
0
Struggling to juggle your daily tasks while keeping your energy levels up? It's time to focus on energy conservation for a better quality of life! Sonja Braasch, OTR/L, senior occupational therapist, shares how you can save #energy for the things you love and need to do. 💪💡
0
1
0
Please join us in welcoming our incoming class of physician #residents. Our residency program is known for its innovative learning environments, delivering on the Providence Mission and training our future physicians. #ProvidenceSwedish #ProvidenceSwedishEverett #WSU
0
1
2
Navigating Neoadjuvant vs Adjuvant Immunotherapy Approaches in NSCLC Requires Further Elucidation @ProvSwedCancRes #lcsm #oncology #MedTwitter
https://t.co/1nnQsh9GyB
onclive.com
Sid Devarakonda, MD, details how new treatment strategies in the neoadjuvant and adjuvant settings are being implemented in the non–small cell lung cancer arena.
0
1
0
Sid Devarakonda, MD, expands on the significance of OS data when evaluating a treatment for efficacy in NSCLC and noted the potential value of additional end points including pCR and EFS. @ProvSwedCancRes #lcsm #oncology #MedTwitter
https://t.co/Q03zqRsBYW
0
1
1
Amazing Thoracic Oncology session with Dr. Diane Tseng (@UWMedicine/@fredhutch), @AngelQinMD (@umichmedicine), & Dr. Siddhartha Devarakonda (@ProvSwedish) here at #BestofASCO24 📍Seattle!
0
1
2
Sunshine Gray presents on nursing experience with #tarlatamab at the oncology nursing society congress. So glad for the critical efforts of our RNs on our research team and the recent FDA approval of this #bispecific for #smallcelllungcancer
ons.confex.com
Background/Significance: Tarlatamab is an investigational BiTE® immunotherapy t...
0
1
1
Dr. Krish Patel contributes to national guidelines on bispecific antibodies which are available at @ProvSwedish in both #clinicaltrials and as #standardofcare @ProvSwedCancRes
ashpublications.org
CD3×CD20 bispecific antibody therapies instigate a T-cell mediated immune response to B-cell lymphoid cancers and are a major new class of treatment for pa
0
0
0
@ProvSwedCancRes researchers study rising incidence of #angiosarcoma in the United States in collaboration with @DanaFarber @ClevelandClinic @DukeU @fredhutch and others. @JAMANetworkOpen
jamanetwork.com
This cross-sectional study uses data from the US Cancer Statistics National Program of Cancer Registries–Surveillance, Epidemiology, and End Results Combined Database to describe the incidence,...
0
0
0
Using AI deep learning to help understand cancer risk over time: no impact on vitamin D supplements on breast cancer risk using radiographic measures #swog
academic.oup.com
Abstract. Deep learning–based mammographic evaluations could noninvasively assess response to breast cancer chemoprevention. We evaluated change in a convo
0
0
0
Dr. Jed Gorden also publishes on reducing health disparities in #lungcancer
link.springer.com
Cancer and Metastasis Reviews - Inequitable access to care continues to hinder improvements in diagnosis and treatment of lung cancer. This review describes healthcare disparities in the changing...
0
0
0
Dr Jed Gorden @ProvSwedCancRes publishes on increasing access to #screening for #lungcancer in @accpchest
https://t.co/aQKy75gq3z
#prevention 🩻🫁
journal.chestnet.org
Rural and socioeconomically disadvantaged areas face significant disparities. The E2SFCA models demonstrated that capacity is an important component and how geographic access and availability jointly...
0
0
0
Dr. Charles Cobbs @ProvSwedCancRes publishes on overcoming treatment escape in glioblastoma:
science.org
Gene regulatory networks drive glioma stem-like cell drug response and drug-induced cell-state transitions leading to resistance.
0
0
1
Dr. Fengting Yan @ProvSwedish publishes in @NatureMedicine on a novel KAT6 inhibitor for advanced #breastcancer
https://t.co/kwLwEIj9h4 👏👏
nature.com
Nature Medicine - In this phase 1 trial, treatment of patients with ER+HER2− metastatic breast cancer with a selective catalytic inhibitor of the lysine acetyltransferase KAT6 shows a...
0
0
0
A year ago today, the @US_FDA approved glofitamab for the treatment of relapsed or refractory #DLBCL. In this podcast episode, @KrishPatelMD, of @ProvSwedCancRes, joins @chadinabhan to outline clinical trial data for this bispecific antibody. 🎧 https://t.co/AyJlXthMKr
0
1
6